National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA.
University of Michigan Medical School, Ann Arbor, MI, USA.
J Diabetes Sci Technol. 2023 Jan;17(1):7-14. doi: 10.1177/19322968221121152. Epub 2022 Sep 3.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Diabetic Foot Consortium (DFC) was established in September 2018 by the NIDDK to build an organization to facilitate the highest quality of clinical research on diabetic foot ulcers (DFUs) that will answer clinically significant questions to improve DFU healing and prevent amputations. The initial focus of the DFC is to develop and validate biomarkers for DFUs that can be used in clinical care and research. The DFC consists of a data coordinating center (DCC) for operational oversight and statistical analysis, clinical sites for participant recruitment and evaluation, and biomarker analysis units (BAUs). The DFC is currently studying biomarkers to predict wound healing and recurrence and is collecting biosamples for future studies through a biorepository. The DFC plans to address the challenges of recruitment and eligibility criteria for DFU clinical trials by taking an approach of "No DFU Patient Goes Unstudied." In this platform approach, clinical history, DFU outcome, wound imaging, and biologic measurements from a large number of patients will be captured and the in-depth longitudinal data set will be analyzed to develop a computational-based DFU risk factor profile to facilitate scientifically sound clinical trial design. The DFC will expand its platform to include studies of the role of social determinants of health, such as food insecurity, housing instability, limited health literacy, and poor social support. The DFC is starting partnerships with the broad group of stakeholders in the wound care community.
美国国立糖尿病、消化和肾脏疾病研究所(NIDDK)糖尿病足联盟(DFC)于 2018 年 9 月由 NIDDK 成立,旨在建立一个组织,以促进最高质量的糖尿病足溃疡(DFU)临床研究,从而回答具有临床意义的问题,以改善 DFU 愈合并预防截肢。DFC 的初始重点是开发和验证可用于临床护理和研究的 DFU 生物标志物。DFC 由一个数据协调中心(DCC)负责运营监督和统计分析、临床站点负责参与者招募和评估以及生物标志物分析单位(BAU)组成。DFC 目前正在研究生物标志物,以预测伤口愈合和复发,并通过生物库收集生物样本,用于未来的研究。DFC 计划通过采取“没有 DFU 患者未被研究”的方法来解决 DFU 临床试验的招募和资格标准挑战。在这种平台方法中,将从大量患者中获取临床病史、DFU 结果、伤口成像和生物测量数据,并对深入的纵向数据集进行分析,以开发基于计算的 DFU 风险因素概况,从而促进科学合理的临床试验设计。DFC 将扩大其平台,包括研究健康的社会决定因素(如粮食不安全、住房不稳定、有限的健康素养和较差的社会支持)的作用。DFC 正在与伤口护理界的广泛利益相关者建立伙伴关系。